12,372 trials
Bleeding
Primary: Percentage of Participants With Intra-operative Hemostasis at the Evaluation Site Within 3 Minutes After Application of the Randomized Treatment — 26.0; 18.0 percentage…
Secondary Hyperparathyroidism · Chronic Kidney Disease
Primary: Percentage of Participants With > 30% Reduction From Baseline in Mean Parathyroid Hormone During the Efficacy Assessment Phase - Non-inferiority Analysis — 63.9; 77.9…
Parenchymous Tissue Surgical Bleeding
Primary: Proportion of Subjects Achieving Hemostasis by Four Minutes After Treatment Start — 92.8; 80.5 Percent of subjects achieving hemostasis
Advanced Parkinson's Disease
Primary: Change From Baseline to Week 12 in the Non-Motor Symptom Scale (NMSS) Total Score — -17.6 units on a scale — p=< 0.001
HIV Infections
Primary: Time to the First New Persistent Infection of HPV 6, 11, 16, or 18 — 1.90; 1.04; 2.92; 2.05 Years — p=0.350
Benign Prostate Hyperplasia · Erectile Dysfunction
Primary: Change From Baseline in Total International Prostate Symptom Score (IPSS) at Week 12 — -4.08; -5.49; -4.92 units on a scale
Haemophilus Influenzae Type b · Diphtheria · Tetanus
Primary: Number of Subjects Reporting Any Solicited Local Symptoms — 130; 120; 89; 134 Participants
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Change From Baseline in Morning -Pre-dose Trough FEV1 Over 52 Weeks — 0.133; 0.076; 0.068; 0.107 Liters
Lung Diseases · Asthma
Primary: Number of Wheezing-free Days of Infant (Observed by Primary Caregiver) — 25.5; 30.5 Days
Acne Vulgaris
Primary: Percentage of Patients With a Score of 0 (None) or 1 (Minimal) on the 5-point Global Acne Assessment Score (GAAS) — 29.8; 20.9 Percentage of Patients
Type 2 Diabetes
Primary: Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF]) — -0.29; -1.04; -1.11 % of hemoglobin — p=<0.0001
Influenza
Primary: Rate of Healthy Adults Aged ≥19 Years With Seroconversion — 47.7; 49.5; 49.0; 78.7 percentage of subjects
Acne Vulgaris
Primary: Percentage of Patients With a Score of 0 (None) or 1 (Minimal) on the 5-point Global Acne Assessment Score (GAAS) — 29.9; 21.2 Percentage of Patients
Hemophilia A With Inhibitors
Primary: Number of Bleeds During 6 Month Treatment Period — 13.1; 5.0 bleeds — p=<0.001
Cerebral Palsy · Muscle Spasticity · Children
Primary: Change in MAS Score in the Gastrocnemius-soleus Complex (GSC) at the Ankle Joint of the (Most) Affected Lower Limb — -0.86; -0.97; -0.48 units on a scale — p=0.0029